High Prices Are Side Effect Of AbbVie-Allergan Deal, Feds Told
Public interest and labor groups have called on the Federal Trade Commission to reject AbbVie's planned $63 billion acquisition of Allergan if the merger threatens consumers with higher drug prices. ...To view the full article, register now.
Already a subscriber? Click here to view full article